Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will evaluate side effects after sublingual misoprostol (600 mcg) as a first-line treatment for primary postpartum hemorrhage (PPH) due to suspected uterine atony.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gynuity Health Projects
• Collaborators: Bill and Melinda Gates Foundation; University of Liverpool
• Treatments: Misoprostol

Criteria

Inclusion Criteria:

• Able and willing to give informed consent

• Vaginal delivery

• Postpartum hemorrhage due to suspected uterine atony

• Oxytocin given during 3rd stage of labor

Exclusion Criteria:

• Known allergy to prostaglandins or misoprostol

• Underwent cesarean section

• Postpartum hemorrhage NOT due to suspected uterine atony

• Oxytocin NOT given during 3rd stage of labor

• Severe ill health

• Unable to give informed consent